Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Ocular Therapeutix completed a positive Pre-NDA meeting with the FDA for AXPAXLI (OTX-TKI) in wet age-related macular degeneration, confirming the planned NDA package. - The NDA will rest on Week 52 efficacy and safety data from the Phase 3 SOL-1 trial, interim safety data from SOL-R, and supporting confirmatory evidence. - Submission remains on track for the fourth quarter of 2026 under the 505(b)(2) pathway, which could shorten FDA review by up to 60 days. - If approved, AXPAXLI could become the first tyrosine kinase inhibitor marketed for wet AMD, with commercial readiness accelerating ahead of a potential 2027 launch.
- At ASRS 2026 in Montreal, durable treatment strategies for wet AMD dominated research, with gene therapy, intravitreal implant and optogenetic data presented across four days. - Ocular Therapeutix reported phase 3 SOL-1 results showing a single AXPAXLI injection maintained BCVA in 74.1% of patients at Week 36 versus 55.8% with monthly aflibercept. - Nanoscope Therapeutics presented 3-year REMAIN data showing durable BCVA gains of about 3 ETDRS lines with MCO-010 in retinitis pigmentosa, alongside a rolling BLA submission. - Belite Bio's phase 3 DRAGON trial of oral tinlarebant met its primary endpoint with a 36% reduction in retinal lesion growth versus placebo in Stargardt disease.
- The FDA approved Roche's Susvimo (ranibizumab injection) 100 mg/mL in May 2025 as the first continuous-delivery therapy for diabetic retinopathy, requiring only one refill every nine months. - The approval was supported by positive data from the Phase III Pavilion trial and applies to patients who have previously responded to at least two anti-VEGF injections. - Diabetic retinopathy affects nearly 10 million people in the US and over 100 million worldwide, with prevalence rising with age and affecting 15–30% of the diabetic population. - The diabetic retinopathy market is projected to grow significantly through 2036, driven by rising diabetes prevalence, novel pipeline candidates, and sustained-release treatment innovations.
- An independent safety committee found no new concerns in EyePoint's two late-stage trials of Duravyu for wet age-related macular degeneration and recommended the studies continue unchanged. - The trials have enrolled more than 900 patients and are evaluating Duravyu against Regeneron's blockbuster eye drug Eylea, with topline data expected in mid-2026. - Interim safety data showed a continued favorable safety profile, consistent with results from more than 190 patients across four earlier trials. - The drug is also being tested in late-stage studies for diabetic macular edema, with data expected in the second half of 2027.
- Sanofi is reportedly preparing a sweetened acquisition offer for Ocular Therapeutix after its initial $16 per share bid was rejected last summer for undervaluing the company. - The French pharmaceutical giant is targeting Ocular's late-stage ophthalmology pipeline, particularly Axpaxli for wet age-related macular degeneration, which is in Phase 3 trials designed to show superiority over Eylea. - Ocular Therapeutix currently trades at $11.28 per share with a market valuation of approximately $2.4 billion, while its Axpaxli candidate addresses a total addressable market exceeding $10 billion. - The potential acquisition would provide Sanofi access to Ocular's drug delivery platform Elutyx and help offset anticipated patent expirations for its blockbuster drug Dupixent in the early 2030s.
- Tyrosine kinase inhibitors EYP-1901 and OTX-TKI have demonstrated preliminary results similar to aflibercept 2 mg in treating wet age-related macular degeneration. - Multiple gene therapy programs including ABBV-RGX-314, 4D-150, and ADVM-022 are currently under investigation for neovascular AMD treatment. - Vorolanib is designed for 6-month dosing intervals, potentially reducing treatment burden for wet AMD patients. - Experts anticipate numerous clinical readouts in the next year or two that could expand treatment options for neovascular AMD patients.
- Ocular Therapeutix has randomized the first patient in HELIOS-3, a Phase 3 registrational trial evaluating AXPAXLI for non-proliferative diabetic retinopathy (NPDR). - The HELIOS program comprises two complementary superiority studies targeting a broad diabetic retinopathy label, with AXPAXLI potentially offering treatment as infrequent as every 12 months. - Despite over 6 million NPDR patients in the U.S., fewer than 1% currently receive therapy due to the burden of frequent injections in this working-age population. - HELIOS-1 trial results showed no patients in the AXPAXLI arm developed proliferative diabetic retinopathy or center-involved diabetic macular edema through 48 weeks, compared to 37.5% in the control arm.
- Ocular Therapeutix is conducting two Phase 3 clinical studies (SOL-1 and SOL-R) evaluating OTX-TKI (Axpaxli), a novel tyrosine kinase inhibitor delivered through a proprietary hydrogel platform for wet age-related macular degeneration. - The SOL-1 superiority study compares a single injection of Axpaxli versus Eylea in treatment-naive patients, with primary outcomes at 9 months and results expected in Q1 2026. - OTX-TKI offers sustained drug release lasting up to 9 months through a 25-gauge intravitreal injection, with the polymer disappearing as the drug is depleted to provide clear re-dosing guidance. - The treatment represents the first potential FDA-approved tyrosine kinase inhibitor for ophthalmology, blocking all three VEGF receptors with zero-order kinetics drug release.
- The HELIOS Phase 1 trial demonstrated that OTX-TKI, a sustained-release axitinib formulation, significantly reduced retinal fluid and vascular leakage in patients with moderately severe to severe diabetic retinopathy without center-involving diabetic macular edema. - OTX-TKI showed sustained therapeutic effects over the entire 12-month study period, with consistent reduction in overall retinal volume measurements and intraretinal fluid compared to sham treatment. - The treatment candidate offers potential dosing every 6 to 12 months, representing a significant reduction in treatment burden for diabetic retinopathy patients. - Two pivotal trials, HELIOS-2 and HELIOS-3, are planned to further evaluate OTX-TKI's efficacy using a novel ordinal DRSS endpoint developed in collaboration with the FDA.
- A phase 4 multicenter study demonstrated that perfluorohexyloctane (MIEBO) provides significant dry eye symptom relief within just 5 minutes of application, showing nearly 50% improvement that continued to increase at subsequent timepoints. - Patients reported high satisfaction with the treatment, with median satisfaction scores rising from 83.0 at Day 3 to 90.0 by Day 14, potentially supporting better treatment adherence for dry eye disease management. - The medication's unique mechanism creates a barrier at the air-tear film interface that reduces evaporation, offering both rapid onset and sustained relief across multiple symptom domains including dryness, burning, irritation, and blurred vision.
